D0118 | Tenofovir

Molecular Formula C9H14N5O4P
Molecular Weight 287.21
State solid
Clearance The clearance of tenofovir is highly dependent on the patient renal stage and hence the clearance rate in patients with renal impairment is reported to be of 134 ml/min while in patients with normal function the clearance rate can be of 210 ml/min.[A178525]
Volume of distribution Accumulation of tenofovir in plasma is related to the presence of nephrotoxic effects.[A178060] It is reported that tenofovir presents a volume of distribution of 0.813 L/kg.[A16539]
Route of elimination Tenofovir is eliminated in the urine by tubular secretion and glomerular filtration. The elimination of this compound is driven by the activity of the human organic anion transporters 1 and 3 and its secretion is mainly ruled by the activity of the multidrug resistance-associated protein 4.[A178060]
Protein binding Tenofovir is minimally bound to plasma proteins and only about 7.2% of the administered dose is found in the bound state.[A16539]
Half life The reported half-life of tenofovir is of 32 hours.[A178231]
Absorption Tenofovir as the active moiety presents a very low bioavailability when orally administered. Hence, the administration of this active agent is required to be under its two prodrug forms, [tenofovir disoproxil] and [tenofovir alafenamide]. This reduced absorption is suggested to be related to the presence of two negative charges among its structure. This negative charge limits its cellular penetration, and its passive diffusion across cellular membranes and intestinal mucosa hindering its availability for oral administration.[A178060] Intravenous tenofovir has been shown to produce a maximum plasma concentration of 2500 ng/ml with an AUC of 4800 ng.h/ml.[A18473]
Trade names Viread
Description antiviral; nucleotide analog reverse-transcriptase inhibitor (NtRTI); inhibits viral reverse transcriptase; tenofovir is an acyclic analog of deoxyadenosine 5'-monophosphate (d-AMP);


J05AF07 Tenofovir disoproxil

[J05AF] Nucleoside and nucleotide reverse transcriptase inhibitors



[J] Antiinfectives for systemic use

Toxicity Dose Time Species Model Method Action Positive criterion Reference

Target Dose Time Species Model Method Action Positive criterion Reference
DNA polymerase gamma 194

Pictogram Signal Statements Precautionary Statement Codes

Aggregated GHS information provided by 2 companies from 1 notifications to the ECHA C&L Inventory.

H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

P280, P305+P351+P338, and P310; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Chronic hepatitis B

  • Foetor hepaticus

  • Hepatitis B e antigen positive

  • Hepatocellular injury

  • Infection

  • Liver disorder

  • Fatigue (0.08)

  • Upper respiratory tract infection (0.05)

  • Abdominal pain

  • Asthenia

  • Back pain

  • Body temperature increased

  • Chest pain

  • Decreased appetite

  • Depression

  • Dermatitis

  • Diarrhoea

  • Dizziness

  • Dyspepsia

  • Fasting

  • Flatulence

  • Gastrointestinal pain

  • Glycosuria

  • Headache

  • Hyperhidrosis

  • Insomnia

  • Musculoskeletal discomfort

  • Myalgia

  • Nausea

  • Neuropathy peripheral

  • Pain

  • Pneumonia

  • Rash

  • Vomiting

  • Weight decreased

  • (((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID (R)-(+)-9-[2-Phosphonylmethoxyethyl]adenine
    (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid (R)-9-(2-Phosphonomethoxypropyl)adenine (R)-9-(2-Phosphonoylmethoxypropyl)adenine
    (R)-9-(Phosphonomethoxypropyl)adenine (R)-9-[2-(Phosphonomethoxy)propyl]adenine (R)-9-[2-(phosphonomethoxy) propyl] adenine
    (R)-PMPA (R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
    114611-EP2272516A2 114611-EP2298783A1 127T206
    147127-20-6 24230-EP2298783A1 24230-EP2314590A1
    9-PMPA 9-[(R)-2-(phosphonomethoxy)propyl]adenine AB0017664
    AB01274787-01 AB01274787_02 AB01274787_03
    ABP000917 AC-760 ACN-029240
    AK-33334 AKOS015856701 AKOS015894941
    AM20090678 API0015388 AX8018435
    BCPP000049 BG0625 BR-33334
    BRD-K15891719-001-02-8 C17407 CHEBI:63625
    CHEMBL483 CP-558 CS-1609
    CTK4C5270 D,L-Tenofovir DTXSID9040132
    EC 604-571-2 FT-0601652 GNA & Tenofovir
    GS 1275 GS 1278 GS-1278
    HHA & Tenofovir HMS3264H05 HY-13910
    J90012 KS-5021 KSC525E7B
    PMPA PMPA gel PMPA-(R)
    Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- Phosphonic acid, ((2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-, (R)- Phosphonic acid, P-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-
    Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
    PubChem9452 Q-201787 Q155954
    S-2389 SC-01187 SCHEMBL39724
    SGOIRFVFHAKUTI-ZCFIWIBFSA-N SR-01000883934 SR-01000883934-1
    ST24033314 TFV gel TR-035738
    Tenofovir Tenofovir (Viread) Tenofovir [USAN:INN:BAN]
    Tenofovir gel Tenofovir gel (GS-1278) Tenofovir, >=98% (HPLC)
    Tenofovir,TDF,PMPA/ Truvada UNII-W4HFE001U5
    Viread (prodrug for Tenofovir) W4HFE001U5 ZINC1543475
    [(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methylphosphonic acid [2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY]METHYLPHOSPHONIC ACID [[(1R)-2(6-Amino-9H-Purin-9-Yl)-1-Methylethoxy]Methyl]Phosphonic Acid
    anh. tenofovir anhydrous tenofovir tenofovir (anh.)
    tenofovir (anhydrous) {[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl}phosphonic acid

    DrugBank Name Tenofovir
    DrugBank DB14126
    CAS Number 107021-12-5, 147127-20-6, 206184-49-8
    PubChem Compound 464205
    KEGG Compound ID C17407
    ChEBI 63625
    PharmGKB PA10204
    ChemSpider 408154
    Wikipedia Tenofovir_disoproxil

    1. Dykens et al. (2007)